These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 9116168

  • 21. Evaluation of the predicted secondary structure of bacteriorhodopsin. Prediction of the bovine rhodopsin secondary structure and its sequence similarity with bacteriorhodopsin.
    Nero TL, Louis WJ.
    Biochem Int; 1992 Aug; 27(5):763-70. PubMed ID: 1417909
    [Abstract] [Full Text] [Related]

  • 22. Identification of putative agouti-related protein(87-132)-melanocortin-4 receptor interactions by homology molecular modeling and validation using chimeric peptide ligands.
    Wilczynski A, Wang XS, Joseph CG, Xiang Z, Bauzo RM, Scott JW, Sorensen NB, Shaw AM, Millard WJ, Richards NG, Haskell-Luevano C.
    J Med Chem; 2004 Apr 22; 47(9):2194-207. PubMed ID: 15084118
    [Abstract] [Full Text] [Related]

  • 23. Differences in partial agonist action at cholecystokinin receptors of mouse and rat are dependent on parameters extrinsic to receptor structure: molecular cloning, expression and functional characterization of the mouse type A cholecystokinin receptor.
    Ghanekar D, Hadac EM, Holicky EL, Miller LJ.
    J Pharmacol Exp Ther; 1997 Sep 22; 282(3):1206-12. PubMed ID: 9316827
    [Abstract] [Full Text] [Related]

  • 24. Conformational and molecular modeling studies of beta-cyclodextrin-heptagastrin and the third extracellular loop of the cholecystokinin 2 receptor.
    Giragossian C, Schaschke N, Moroder L, Mierke DF.
    Biochemistry; 2004 Mar 16; 43(10):2724-31. PubMed ID: 15005607
    [Abstract] [Full Text] [Related]

  • 25. Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor.
    Politowska E, Kaźmierkiewicz R, Wiegand V, Fahrenholz F, Ciarkowski J.
    Acta Biochim Pol; 2001 Mar 16; 48(1):83-93. PubMed ID: 11440186
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Crystal structure of the GluR0 ligand-binding core from Nostoc punctiforme in complex with L-glutamate: structural dissection of the ligand interaction and subunit interface.
    Lee JH, Kang GB, Lim HH, Jin KS, Kim SH, Ree M, Park CS, Kim SJ, Eom SH.
    J Mol Biol; 2008 Feb 15; 376(2):308-16. PubMed ID: 18164033
    [Abstract] [Full Text] [Related]

  • 30. Homology models of mu-opioid receptor with organic and inorganic cations at conserved aspartates in the second and third transmembrane domains.
    Zhorov BS, Ananthanarayanan VS.
    Arch Biochem Biophys; 2000 Mar 01; 375(1):31-49. PubMed ID: 10683246
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Insights into the molecular basis of ligand binding by the cholecystokinin receptor.
    Miller LJ, Ding XQ.
    Pancreatology; 2001 Mar 01; 1(4):336-42. PubMed ID: 12120212
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin-2 receptor.
    Giragossian C, Mierke DF.
    Biochemistry; 2002 Apr 09; 41(14):4560-6. PubMed ID: 11926817
    [Abstract] [Full Text] [Related]

  • 35. Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists.
    Van der Bent A, Ter Laak AM, IJzerman AP, Soudijn W.
    Eur J Pharmacol; 1992 Aug 03; 226(4):327-34. PubMed ID: 1397061
    [Abstract] [Full Text] [Related]

  • 36. Intermolecular interactions between cholecystokinin-8 and the third extracellular loop of the cholecystokinin A receptor.
    Giragossian C, Mierke DF.
    Biochemistry; 2001 Apr 03; 40(13):3804-9. PubMed ID: 11300760
    [Abstract] [Full Text] [Related]

  • 37. Modeled structure of a G-protein-coupled receptor: the cholecystokinin-1 receptor.
    Archer-Lahlou E, Tikhonova I, Escrieut C, Dufresne M, Seva C, Pradayrol L, Moroder L, Maigret B, Fourmy D.
    J Med Chem; 2005 Jan 13; 48(1):180-91. PubMed ID: 15634012
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Met-195 of the cholecystokinin-A receptor interacts with the sulfated tyrosine of cholecystokinin and is crucial for receptor transition to high affinity state.
    Gigoux V, Escrieut C, Silvente-Poirot S, Maigret B, Gouilleux L, Fehrentz JA, Gully D, Moroder L, Vaysse N, Fourmy D.
    J Biol Chem; 1998 Jun 05; 273(23):14380-6. PubMed ID: 9603948
    [Abstract] [Full Text] [Related]

  • 40. Characterization of the type A cholecystokinin receptor hormone-binding domain: use of contrasting and complementary methodologies.
    Ding XQ, Miller LJ.
    Peptides; 2001 Aug 05; 22(8):1223-8. PubMed ID: 11457514
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.